<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604383</url>
  </required_header>
  <id_info>
    <org_study_id>4743</org_study_id>
    <secondary_id>B7A-MC-MBCM</secondary_id>
    <nct_id>NCT00604383</nct_id>
  </id_info>
  <brief_title>Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study</brief_title>
  <official_title>Phase 3, Multicenter,Parallel,Randomized Dbl-masked,Placebo-controlled Study of the Effects of 32 mg/dy Ruboxistaurin Vision Loss in Patients With Type 1 or Type 2 Diabetes Mellitus and an Early Treatment Diabetic Retinopathy Study Level Between 47A and 53E.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chromaderm, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chromaderm, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three
      years will reduce vision loss associated with diabetic retinopathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Had Sustained Moderate Visual Loss (SMVL) as Defined as a Visual Acuity Loss of ≥15 Letters Measured Twice During a 6-month Period</measure>
    <time_frame>Baseline through 36 months</time_frame>
    <description>SMVL is defined as a ≥15-letter decrease from baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) that the participant sustained during the last 6 months of study participation (Months 30-36). Participants who discontinued the study early may have had SMVL if there was a 6-month period of ≥15 letters lost in VA ending with the last visit at which VA was assessed. ETDRS visual acuity uses an eye chart with 5 letters per line. The scores range from 0 (no letters read correctly) to 100 (all letters read correctly). Percentage of participants = (number of participants who had SMVL) / (number of participants who were randomized) * 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Developed Center Involved or Imminently Threatened Diabetic Macular Edema (DME)</measure>
    <time_frame>Baseline through 36 months</time_frame>
    <description>DME is the accumulation of extracellular fluid in the retinal tissue of the macular area, which can reduce the ability for fine visual discrimination. Percentage of participants = (number of participants who developed center involved or imminently threatened DME) / (number of participants who had no center involved or imminently threatened DME at baseline) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced the Development of Proliferative Diabetic Retinopathy (PDR)</measure>
    <time_frame>Baseline through 36 months</time_frame>
    <description>Percentage of participants = (number of participants who experienced the development of PDR) / (number of participants who were randomized) * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline up to 36 Months in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25)</measure>
    <time_frame>Baseline, up to 36 months</time_frame>
    <description>NEI-VFQ-25 consisted of 25 questions and was used to measure the influence of visual disability and symptoms on general health of participants. The possible total score range for the NEI-VFQ-25 was from 0 (worst possible outcome) to 100 (best possible outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline up to 36 Months in Mental and Physical Components of the Medical Outcomes Study 36-Item Short Form (SF-36) Health Status Questionnaire</measure>
    <time_frame>Baseline, up to 36 months</time_frame>
    <description>SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions. There are 2 component scores, mental component score (MCS) and physical component score (PCS). MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. Both MCS and PCS have scores ranging from 0 to 100 with higher scores indicating better mental or physical health.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">685</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Ruboxistaurin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ruboxistaurin</intervention_name>
    <description>32-mg tablet, orally, daily, up to 42 months</description>
    <arm_group_label>Ruboxistaurin</arm_group_label>
    <other_name>LY333531</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1 tablet, orally, daily, up to 42 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 or Type 2 diabetes mellitus

          -  18 years or older

          -  Meet specific requirements for diabetic retinopathy

          -  Free of severe or chronically disabling conditions, except diabetes, diabetic
             retinopathy and diabetic macular edema

          -  Hemoglobin A1c (HbA1C) ≤13.0%

        Exclusion Criteria:

          -  History of panretinal photocoagulation for diabetic retinopathy, conditions that might
             affect the progression of diabetic retinopathy, or unstable angina

          -  Investigators, site personnel directly affiliated with the study and their families

          -  Presence of eye disorders that may affect the progression of diabetic retinopathy or
             cause vision loss

          -  Presence of medical disorder, cancer, or elevated laboratory measurements that could
             represent a safety risk during the study

          -  Women who are pregnant, breastfeeding, intend to become pregnant, or who are sexually
             active without using an acceptable method of birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl Beutner</last_name>
    <role>Study Director</role>
    <affiliation>Chromaderm, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT -5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2008</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <results_first_submitted>December 22, 2015</results_first_submitted>
  <results_first_submitted_qc>December 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 28, 2016</results_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ruboxistaurin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study consisted of a 36-month treatment phase and a 0 to 6-month extended treatment phase. Completers are those who completed the 36-month treatment phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ruboxistaurin</title>
          <description>One 32-milligram (mg) tablet, orally, daily, for up to 42 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>1 tablet, orally, daily, for up to 42 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="345"/>
                <participants group_id="P2" count="340"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="345"/>
                <participants group_id="P2" count="340"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Extended Treatment</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="258"/>
                <participants group_id="P2" count="256"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Ruboxistaurin</title>
          <description>One 32-mg tablet, orally, daily, for up to 42 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>1 tablet, orally, daily, for up to 42 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="345"/>
            <count group_id="B2" value="340"/>
            <count group_id="B3" value="685"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.48" spread="10.91"/>
                    <measurement group_id="B2" value="59.18" spread="10.61"/>
                    <measurement group_id="B3" value="59.33" spread="10.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="215"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African Descent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="259"/>
                    <measurement group_id="B2" value="273"/>
                    <measurement group_id="B3" value="532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East/Southeast Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Western Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="345"/>
                    <measurement group_id="B2" value="340"/>
                    <measurement group_id="B3" value="685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Had Sustained Moderate Visual Loss (SMVL) as Defined as a Visual Acuity Loss of ≥15 Letters Measured Twice During a 6-month Period</title>
        <description>SMVL is defined as a ≥15-letter decrease from baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) that the participant sustained during the last 6 months of study participation (Months 30-36). Participants who discontinued the study early may have had SMVL if there was a 6-month period of ≥15 letters lost in VA ending with the last visit at which VA was assessed. ETDRS visual acuity uses an eye chart with 5 letters per line. The scores range from 0 (no letters read correctly) to 100 (all letters read correctly). Percentage of participants = (number of participants who had SMVL) / (number of participants who were randomized) * 100.</description>
        <time_frame>Baseline through 36 months</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ruboxistaurin</title>
            <description>One 32-mg tablet, orally, daily, for 36 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 tablet, orally, daily, for 36 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Had Sustained Moderate Visual Loss (SMVL) as Defined as a Visual Acuity Loss of ≥15 Letters Measured Twice During a 6-month Period</title>
          <description>SMVL is defined as a ≥15-letter decrease from baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) that the participant sustained during the last 6 months of study participation (Months 30-36). Participants who discontinued the study early may have had SMVL if there was a 6-month period of ≥15 letters lost in VA ending with the last visit at which VA was assessed. ETDRS visual acuity uses an eye chart with 5 letters per line. The scores range from 0 (no letters read correctly) to 100 (all letters read correctly). Percentage of participants = (number of participants who had SMVL) / (number of participants who were randomized) * 100.</description>
          <population>All randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="345"/>
                <count group_id="O2" value="340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Developed Center Involved or Imminently Threatened Diabetic Macular Edema (DME)</title>
        <description>DME is the accumulation of extracellular fluid in the retinal tissue of the macular area, which can reduce the ability for fine visual discrimination. Percentage of participants = (number of participants who developed center involved or imminently threatened DME) / (number of participants who had no center involved or imminently threatened DME at baseline) * 100.</description>
        <time_frame>Baseline through 36 months</time_frame>
        <population>All randomized participants who had no center involved or imminently threatened DME at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ruboxistaurin</title>
            <description>One 32-mg tablet, orally, daily, for 36 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 tablet, orally, daily, for 36 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Developed Center Involved or Imminently Threatened Diabetic Macular Edema (DME)</title>
          <description>DME is the accumulation of extracellular fluid in the retinal tissue of the macular area, which can reduce the ability for fine visual discrimination. Percentage of participants = (number of participants who developed center involved or imminently threatened DME) / (number of participants who had no center involved or imminently threatened DME at baseline) * 100.</description>
          <population>All randomized participants who had no center involved or imminently threatened DME at baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced the Development of Proliferative Diabetic Retinopathy (PDR)</title>
        <description>Percentage of participants = (number of participants who experienced the development of PDR) / (number of participants who were randomized) * 100.</description>
        <time_frame>Baseline through 36 months</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ruboxistaurin</title>
            <description>One 32-mg tablet, orally, daily, for 36 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 tablet, orally, daily, for 36 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced the Development of Proliferative Diabetic Retinopathy (PDR)</title>
          <description>Percentage of participants = (number of participants who experienced the development of PDR) / (number of participants who were randomized) * 100.</description>
          <population>All randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="345"/>
                <count group_id="O2" value="340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9"/>
                    <measurement group_id="O2" value="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline up to 36 Months in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25)</title>
        <description>NEI-VFQ-25 consisted of 25 questions and was used to measure the influence of visual disability and symptoms on general health of participants. The possible total score range for the NEI-VFQ-25 was from 0 (worst possible outcome) to 100 (best possible outcome).</description>
        <time_frame>Baseline, up to 36 months</time_frame>
        <population>All randomized participants with evaluable NEI-VFQ-25 total score. Last Observation Carried Forward (LOCF) was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Ruboxistaurin</title>
            <description>One 32-mg tablet, orally, daily, for 36 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 tablet, orally, daily, for 36 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline up to 36 Months in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25)</title>
          <description>NEI-VFQ-25 consisted of 25 questions and was used to measure the influence of visual disability and symptoms on general health of participants. The possible total score range for the NEI-VFQ-25 was from 0 (worst possible outcome) to 100 (best possible outcome).</description>
          <population>All randomized participants with evaluable NEI-VFQ-25 total score. Last Observation Carried Forward (LOCF) was used to impute missing post-baseline values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.82" spread="14.75"/>
                    <measurement group_id="O2" value="-4.10" spread="13.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline up to 36 Months in Mental and Physical Components of the Medical Outcomes Study 36-Item Short Form (SF-36) Health Status Questionnaire</title>
        <description>SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions. There are 2 component scores, mental component score (MCS) and physical component score (PCS). MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. Both MCS and PCS have scores ranging from 0 to 100 with higher scores indicating better mental or physical health.</description>
        <time_frame>Baseline, up to 36 months</time_frame>
        <population>All randomized participants with evaluable SF-36 MCS and PCS. LOCF was used to impute missing post-baseline values</population>
        <group_list>
          <group group_id="O1">
            <title>Ruboxistaurin</title>
            <description>One 32-mg tablet, orally, daily, for 36 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 tablet, orally, daily, for 36 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline up to 36 Months in Mental and Physical Components of the Medical Outcomes Study 36-Item Short Form (SF-36) Health Status Questionnaire</title>
          <description>SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions. There are 2 component scores, mental component score (MCS) and physical component score (PCS). MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. Both MCS and PCS have scores ranging from 0 to 100 with higher scores indicating better mental or physical health.</description>
          <population>All randomized participants with evaluable SF-36 MCS and PCS. LOCF was used to impute missing post-baseline values</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.21" spread="70.91"/>
                    <measurement group_id="O2" value="-19.85" spread="70.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.63" spread="84.92"/>
                    <measurement group_id="O2" value="-29.15" spread="79.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ruboxistaurin</title>
          <description>One 32-mg tablet, orally, daily, for up to 42 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>1 tablet, orally, daily, for up to 42 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="345"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="345"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypersplenism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="345"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="345"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Aortic valve disease mixed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="345"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="38" subjects_affected="25" subjects_at_risk="345"/>
                <counts group_id="E2" events="26" subjects_affected="19" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cor pulmonale chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Coronary artery atherosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="38" subjects_affected="30" subjects_at_risk="345"/>
                <counts group_id="E2" events="33" subjects_affected="30" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypertensive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Inner ear disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Retinal neovascularisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Colonic haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Mallory-weiss syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Uvulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="345"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Portal hypertensive gastropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="345"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Fungal cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="345"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="345"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Postoperative infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Septic embolus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Chemical burn of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Closed head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="345"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Lung injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Procedural hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Shunt occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose fluctuation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Coagulation time abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Electrocardiogram qt prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Lower limb deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Spinal meningioma benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Squamous endometrial carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anoxic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cerebral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="345"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Demyelinating polyneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="345"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="345"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Priapism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Chronic obstructive airways disease exacerbated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Restrictive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Carotid endarterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="345"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypoperfusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Peripheral occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 8.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="314" subjects_at_risk="345"/>
                <counts group_id="E2" subjects_affected="322" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="345"/>
                <counts group_id="E2" events="37" subjects_affected="36" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="345"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="30" subjects_affected="22" subjects_at_risk="345"/>
                <counts group_id="E2" events="28" subjects_affected="18" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="345"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="345"/>
                <counts group_id="E2" events="26" subjects_affected="19" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" events="26" subjects_affected="19" subjects_at_risk="345"/>
                <counts group_id="E2" events="26" subjects_affected="20" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" events="26" subjects_affected="19" subjects_at_risk="345"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="345"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="345"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="37" subjects_affected="32" subjects_at_risk="345"/>
                <counts group_id="E2" events="104" subjects_affected="40" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="345"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="345"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="33" subjects_affected="26" subjects_at_risk="345"/>
                <counts group_id="E2" events="46" subjects_affected="37" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="345"/>
                <counts group_id="E2" events="56" subjects_affected="33" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="18" subjects_at_risk="345"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="345"/>
                <counts group_id="E2" events="32" subjects_affected="22" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="345"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="73" subjects_affected="61" subjects_at_risk="345"/>
                <counts group_id="E2" events="99" subjects_affected="67" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="19" subjects_at_risk="345"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="30" subjects_affected="24" subjects_at_risk="345"/>
                <counts group_id="E2" events="38" subjects_affected="29" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="55" subjects_affected="44" subjects_at_risk="345"/>
                <counts group_id="E2" events="49" subjects_affected="45" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="29" subjects_affected="21" subjects_at_risk="345"/>
                <counts group_id="E2" events="29" subjects_affected="22" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="91" subjects_affected="59" subjects_at_risk="345"/>
                <counts group_id="E2" events="112" subjects_affected="67" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="345"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="345"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="38" subjects_affected="25" subjects_at_risk="345"/>
                <counts group_id="E2" events="43" subjects_affected="32" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="29" subjects_affected="23" subjects_at_risk="345"/>
                <counts group_id="E2" events="51" subjects_affected="35" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="33" subjects_affected="25" subjects_at_risk="345"/>
                <counts group_id="E2" events="44" subjects_affected="31" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="345"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="345"/>
                <counts group_id="E2" events="23" subjects_affected="17" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="345"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="345"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="345"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="345"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="345"/>
                <counts group_id="E2" events="44" subjects_affected="36" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="345"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="36" subjects_affected="32" subjects_at_risk="345"/>
                <counts group_id="E2" events="34" subjects_affected="27" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="32" subjects_affected="27" subjects_at_risk="345"/>
                <counts group_id="E2" events="39" subjects_affected="29" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="345"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="44" subjects_affected="38" subjects_at_risk="345"/>
                <counts group_id="E2" events="50" subjects_affected="35" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="345"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="40" subjects_affected="29" subjects_at_risk="345"/>
                <counts group_id="E2" events="30" subjects_affected="27" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="39" subjects_affected="33" subjects_at_risk="345"/>
                <counts group_id="E2" events="59" subjects_affected="45" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="345"/>
                <counts group_id="E2" events="36" subjects_affected="33" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="345"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="345"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="345"/>
                <counts group_id="E2" events="33" subjects_affected="31" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="78" subjects_affected="57" subjects_at_risk="345"/>
                <counts group_id="E2" events="60" subjects_affected="42" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="35" subjects_affected="29" subjects_at_risk="345"/>
                <counts group_id="E2" events="33" subjects_affected="30" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="28" subjects_affected="18" subjects_at_risk="345"/>
                <counts group_id="E2" events="35" subjects_affected="29" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="345"/>
                <counts group_id="E2" events="28" subjects_affected="21" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="58" subjects_affected="58" subjects_at_risk="345"/>
                <counts group_id="E2" events="50" subjects_affected="50" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>info@chroma-derm.com</name_or_title>
      <organization>Chromaderm</organization>
      <email>info@chroma-derm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

